Biotech company CSL (ASX:CSL) is advancing its Research & Development (R&D) pipeline and capabilities to deliver a highly differentiated product portfolio mix, addressing a broader range of patients’ unmet needs.
During their annual R&D briefing to investors it was noted that the company is building on its leadership in plasma therapies through the identification of emerging new medicines.
They are collaborating with universities across the globe and have over 1,700 scientists working on therapies for challenging medical conditions.
In FY19, CSL invested US$832 million into its R&D portfolio, representing 9.7% of total revenues.
Shares in CSL (ASX:CSL) are trading 0.9 per cent lower at $275.38.